Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK.
Leukemia. 2022 Mar;36(3):625-636. doi: 10.1038/s41375-021-01448-2. Epub 2021 Oct 16.
Chromosomal abnormalities are established prognostic markers in adult ALL. We assessed the prognostic impact of established chromosomal abnormalities and key copy number alterations (CNA) among 652 patients with B-cell precursor ALL treated on a modern MRD driven protocol. Patients with KMT2A-AFF1, complex karyotype (CK) and low hypodiploidy/near-triploidy (HoTr) had high relapse rates 50%, 60% & 53% and correspondingly poor survival. Patients with BCR-ABL1 had an outcome similar to other patients. JAK-STAT abnormalities (CRLF2, JAK2) occurred in 6% patients and were associated with a high relapse rate (56%). Patients with ABL-class fusions were rare (1%). A small group of patients with ZNF384 fusions (n = 12) had very good survival. CNA affecting IKZF1, CDKN2A/B, PAX5, BTG1, ETV6, EBF1, RB1 and PAR1 were assessed in 436 patients. None of the individual deletions or profiles were associated with survival, either in the cohort overall or within key subgroups. Collectively these data indicate that primary genetic abnormalities are stronger prognostic markers than secondary deletions. We propose a revised UKALL genetic risk classification based on key established chromosomal abnormalities: (1) very high risk: CK, HoTr or JAK-STAT abnormalities; (2) high risk: KMT2A fusions; (3) Tyrosine kinase activating: BCR-ABL1 and ABL-class fusions; (4) standard risk: all other patients.
染色体异常是成人 ALL 的明确预后标志物。我们评估了在 652 例接受现代基于 MRD 驱动的方案治疗的 B 细胞前体 ALL 患者中,已确定的染色体异常和关键拷贝数改变(CNA)的预后影响。具有 KMT2A-AFF1、复杂核型(CK)和低亚二倍体/近三倍体(HoTr)的患者复发率高(分别为 50%、60%和 53%),相应的生存率也较差。具有 BCR-ABL1 的患者结局与其他患者相似。JAK-STAT 异常(CRLF2、JAK2)发生在 6%的患者中,与高复发率(56%)相关。ABL 类融合的患者很少见(1%)。一小部分具有 ZNF384 融合的患者(n=12)有非常好的生存。在 436 例患者中评估了影响 IKZF1、CDKN2A/B、PAX5、BTG1、ETV6、EBF1、RB1 和 PAR1 的 CNA。在整个队列或关键亚组中,没有一个单独的缺失或图谱与生存相关。这些数据共同表明,原发性遗传异常是比继发性缺失更强的预后标志物。我们根据关键的已确定染色体异常提出了一种新的 UKALL 遗传风险分类:(1)极高风险:CK、HoTr 或 JAK-STAT 异常;(2)高风险:KMT2A 融合;(3)酪氨酸激酶激活:BCR-ABL1 和 ABL 类融合;(4)标准风险:所有其他患者。